Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.38.

CLDX has been the subject of several recent analyst reports. Bank of America raised shares of Celldex Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 15th. Zacks Investment Research raised shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Monday, January 14th. ValuEngine raised shares of Celldex Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, February 13th. Finally, HC Wainwright set a $19.00 price objective on shares of Celldex Therapeutics and gave the company a “buy” rating in a research note on Tuesday, April 2nd.

Several hedge funds and other institutional investors have recently made changes to their positions in CLDX. BlackRock Inc. grew its stake in shares of Celldex Therapeutics by 6.2% during the 3rd quarter. BlackRock Inc. now owns 3,801,667 shares of the biopharmaceutical company’s stock valued at $1,715,000 after buying an additional 223,231 shares during the period. Renaissance Technologies LLC grew its stake in shares of Celldex Therapeutics by 26.6% during the 3rd quarter. Renaissance Technologies LLC now owns 5,343,599 shares of the biopharmaceutical company’s stock valued at $2,410,000 after buying an additional 1,122,912 shares during the period. Vanguard Group Inc. grew its stake in shares of Celldex Therapeutics by 7.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,047,564 shares of the biopharmaceutical company’s stock valued at $2,728,000 after buying an additional 421,700 shares during the period. Vanguard Group Inc grew its stake in shares of Celldex Therapeutics by 7.5% during the 3rd quarter. Vanguard Group Inc now owns 6,047,564 shares of the biopharmaceutical company’s stock valued at $2,728,000 after buying an additional 421,700 shares during the period. Finally, Acadian Asset Management LLC grew its stake in shares of Celldex Therapeutics by 26.5% during the 4th quarter. Acadian Asset Management LLC now owns 1,373,376 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 287,281 shares during the period.

CLDX stock traded down $0.24 during midday trading on Monday, hitting $3.11. The stock had a trading volume of 353,500 shares, compared to its average volume of 458,489. The stock has a market capitalization of $46.13 million, a P/E ratio of -0.46 and a beta of 4.13. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.86 and a current ratio of 7.41. Celldex Therapeutics has a 12-month low of $2.74 and a 12-month high of $11.63.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.95) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.20) by $0.25. The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.46 million. Celldex Therapeutics had a negative net margin of 729.59% and a negative return on equity of 45.09%. Research analysts forecast that Celldex Therapeutics will post -4.69 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, currently being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in multiple types of solid tumors and B cell lymphomas; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-301, a dendritic cell growth factor; and Varlilumab, an immune modulating antibody targeting CD27 designed to enhance a patient's immune response.

Further Reading: What is the price-sales ratio?

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.